#1
Moderna
The mRNA pioneer that peaked at $18B revenue. Beyond COVID, Moderna's platform is attacking flu, HIV, and cancer with personalized mRNA vaccines. Its 2023 RSV vaccine approval validated mRNA as a universal medicine-making technology, with a pipeline value estimated at $50B.
Photos (1)
Comments on "Moderna"
Have a take on this ranking?
Comments are how the argument actually happens here. Posting one needs a free account — it takes about a minute.
No comments yet.
The first comment sets the terms of the argument.